The National Medical Products Administration (NMPA) in China has recently approved Sichuan Kelun Biotech Biopharmaceutical’s Sutaray (trastuzumab botidotin) for the treatment of adult patients with... The post Sutaray NMPA approval marks major milestone in China HER2-positive breast cancer market, says GlobalData appeared first on GlobalData.| GlobalData